Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
Body unavailable. Use the original source.
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.